PMID- 37184460
OWN - NLM
STAT- MEDLINE
DCOM- 20231102
LR  - 20231102
IS  - 2300-9020 (Electronic)
IS  - 1644-387X (Linking)
VI  - 60
IP  - 3
DP  - 2023 Jul-Sep
TI  - Epitope-based vaccine design against the membrane and nucleocapsid proteins of 
      SARS-CoV-2.
PG  - 489-495
LID - 10.17219/dmp/161742 [doi]
AB  - BACKGROUND: The high prevalence and mortality rate of coronavirus disease 2019 
      (COVID-19) is a major global concern. Bioinformatics approaches have helped to 
      develop new strategies to combat infectious agents, including severe acute 
      respiratory syndrome coronavirus 2 (SARS-CoV-2). Indeed, the structural proteins 
      of microorganisms provide suitable epitopes for the development of vaccines to 
      prevent infectious diseases. OBJECTIVES: The present study aimed to use 
      bioinformatics tools to find peptides from the membrane (M) and nucleocapsid (N) 
      proteins with effective cellular and humoral immunogenicity. MATERIAL AND 
      METHODS: Sequences of the M and N proteins were sourced from the National Center 
      for Biotechnology Information (NCBI). The conserved regions of the proteins with 
      the highest immunogenicity were identified and assessed using different servers, 
      and the physicochemical and biochemical properties of the epitopes were 
      evaluated. Finally, allergenicity, antigenicity and docking to human leukocyte 
      antigen (HLA) were investigated. RESULTS: The data indicated that the best 
      epitopes were LVIGFLFLT and LFLTWICLL (as membrane epitopes), and KLDDKDPNFKDQ 
      (as a nucleocapsid epitope), with significant immunogenicity and no evidence of 
      allergenicity. The 3 epitopes are stable peptides that can interact with HLA to 
      induce strong immune responses. CONCLUSIONS: The findings indicate that 3 common 
      epitopes could effectively elicit an immune response against the disease. Hence, 
      in vitro and in vivo studies are recommended to confirm the theoretical 
      information.
FAU - Moballegh Naseri, Mona
AU  - Moballegh Naseri M
AD  - Cellular and Molecular Research Center, Qom University of Medical Sciences, Iran.
FAU - Moballegh Naseri, Mohammad
AU  - Moballegh Naseri M
AD  - Department of Computer and IT, Shahab Danesh University, Qom, Iran.
FAU - Maurya, Vineet Kumar
AU  - Maurya VK
AD  - Department of Botany and Microbiology, H.N.B. Garhwal University, Srinagar, 
      India.
FAU - Shams, Saeed
AU  - Shams S
AD  - Cellular and Molecular Research Center, Qom University of Medical Sciences, Iran.
FAU - Pitaloka, Dian Ayu Eka
AU  - Pitaloka DAE
AD  - Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, 
      Padjadjaran University, Sumedang, Indonesia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Poland
TA  - Dent Med Probl
JT  - Dental and medical problems
JID - 101205669
RN  - 0 (Nucleocapsid Proteins)
RN  - 0 (COVID-19 Vaccines)
RN  - 0 (Viral Vaccines)
RN  - 0 (Epitopes, T-Lymphocyte)
RN  - 0 (Peptides)
SB  - IM
MH  - Humans
MH  - SARS-CoV-2
MH  - *COVID-19/prevention & control
MH  - Nucleocapsid Proteins/chemistry
MH  - COVID-19 Vaccines
MH  - *Viral Vaccines/chemistry
MH  - Epitopes, T-Lymphocyte/chemistry
MH  - Peptides
OTO - NOTNLM
OT  - COVID-19
OT  - HLA
OT  - SARS-CoV-2
OT  - bioinformatics
OT  - multi-epitope vaccine
EDAT- 2023/05/15 13:06
MHDA- 2023/05/15 13:07
CRDT- 2023/05/15 10:33
PHST- 2023/05/15 13:07 [medline]
PHST- 2023/05/15 13:06 [pubmed]
PHST- 2023/05/15 10:33 [entrez]
AID - 10.17219/dmp/161742 [doi]
PST - ppublish
SO  - Dent Med Probl. 2023 Jul-Sep;60(3):489-495. doi: 10.17219/dmp/161742.